A polymer-free, tumor-microenvironment responsive sol–gel platform for spatiotemporal STING activation and self-amplifying immunotherapy
Source abstract
Abstract
Non-nucleotide stimulators of interferon gene (STING) agonists hold promise as immunotherapeutic agents for cancer immunotherapy and postsurgical adjuvant therapy. However, as a prototypical STING agonist, DMXAA suffers from rapid degradation, off-target toxicity, and poor tumor accumulation. Here, we present a polymer-free iRGD-buSS-camptothecin-based sol capable of enhancing drug penetration, activating immune responses, and enabling therapeutic monitoring. This multifunctional sol integrates a tumor-homing cyclic peptide with reducible disulfide-linked camptothecin crosslinkers, enabling in situ sol-gel transition to achieve spatiotemporally controlled delivery of the STING agonist DMXAA into tumor parenchyma. The resulting hydrogel forms a durable drug reservoir with a >30 day tumor retention, where a single low-dose DMXAA (0.2 mg kg-1) triggers potent tumor regression, extends survival, and establishes long-term immunological memory-effectively activating systemic immune surveillance to suppress metastasis. Our strategy synergizes molecularly engineered tumor-targeting precision with spatiotemporal control of STING-driven innate immune activation, circumventing the pharmacological limitations (poor delivery and systemic toxicity) of conventional small-molecule agonists.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: interferon and immune responses · Ubiquitin and proteasome pathways · Immune cells in cancer
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China
Institute of Advanced Equipment, College of Energy Engineering, Zhejiang University, Hangzhou, 310027, China
College of Chemical and Biological Engineering, Zhejiang University, Hangzhou 310058, China
The Seventh Medical Center of Chinese People's Liberation Army General Hospital, Beijing 100010, China
Funding
National Natural Science Foundation of China
References (38)
Show source-provided references
1. Wang · Nat. Commun. · 2018 · 9 · 153210.1038/s41467-018-03915-4 ↗
2. Duan · Angew. Chem., Int. Ed. · 2019 · 58 · 67010.1002/anie.201804882 ↗
3. Liu · Nat. Commun. · 2023 · 14 · 410610.1038/s41467-023-39759-w ↗
4. Haag · Nature · 2018 · 559 · 26910.1038/s41586-018-0287-8 ↗
5. Lanng · Nat. Immunol. · 2024 · 25 · 114410.1038/s41590-024-01872-3 ↗
6. Wilson · Nat. Nanotechnol. · 2024 · 19 · 71810.1038/s41565-024-01637-x ↗
7. Shae · Nat. Nanotechnol. · 2019 · 14 · 26910.1038/s41565-018-0342-5 ↗
8. Sun · Science · 2012 · 339 · 78610.1126/science.1232458 ↗
9. Zhou · Adv. Sci. · 2025 · 12 · 241268710.1002/advs.202412687 ↗
10. Laura · Adv. Sci. · 2025 · 12 · 250029610.1002/advs.202500296 ↗
11. Liu · Chem. Eng. J. · 2023 · 475 · 14647410.1016/j.cej.2023.146474 ↗
12. Wang · J. Am. Chem. Soc. · 2024 · 146 · 2897310.1021/jacs.4c09831 ↗
13. Chen · Adv. Mater. · 2023 · 35 · 221044010.1002/adma.202210440 ↗
14. Garland · Chem. Rev. · 2022 · 122 · 597710.1021/acs.chemrev.1c00750 ↗
15. Feig · Nat. Chem. Eng. · 2025 · 2 · 20910.1038/s44286-025-00194-x ↗
16. Li · Nat. Commun. · 2025 · 16 · 162910.1038/s41467-025-56407-7 ↗
17. Gill · J. Diabetes Sci. Technol. · 2007 · 1 · 72510.1177/193229680700100517 ↗
18. Kranz · Eur. J. Pharm. Sci. · 2008 · 34 · 16410.1016/j.ejps.2008.03.004 ↗
19. Patel · J. Controlled Release · 2010 · 147 · 35010.1016/j.jconrel.2010.08.020 ↗
20. Liang · Chem. Commun. · 2011 · 47 · 123110.1039/C0CC03599H ↗
21. Liang · Adv. Mater. · 2017 · 29 · 170313510.1002/adma.201703135 ↗
22. Brendel · Angew. Chem., Int. Ed. · 2018 · 57 · 1667810.1002/anie.201808543 ↗
23. Peng · Adv. Mater. · 2024 · 36 · 231318810.1002/adma.202313188 ↗
24. Wang · Nat. Biomed. Eng. · 2020 · 4 · 109010.1038/s41551-020-0597-7 ↗
25. Li · Matter · 2024 · 7 · 344710.1016/j.matt.2024.05.041 ↗
26. Sugahara · Cancer Cell · 2009 · 16 · 51010.1016/j.ccr.2009.10.013 ↗
27. Sugahara · J. Clin. Oncol. · 2010 · 28 · e1359010.1200/jco.2010.28.15_suppl.e13590 ↗
28. Chu · Adv. Funct. Mater. · 2020 · 30 · 200591810.1002/adfm.202005918 ↗
29. Zhang · Angew. Chem., Int. Ed. · 2018 · 57 · 706610.1002/anie.201801984 ↗
30. Cao · Biomaterials · 2022 · 290 · 12185610.1016/j.biomaterials.2022.121856 ↗
31. Onyango · Nucleic Acids Res. · 2016 · 44 · 570210.1093/nar/gkw275 ↗
32. Fang · Adv. Funct. Mater. · 2025 · 35 · 242184910.1002/adfm.202421849 ↗
33. Lin · Angew. Chem., Int. Ed. · 2023 · 135 · e20231015810.1002/ange.202310158 ↗
34. Xu · J. Hematol. Oncol. · 2022 · 15 · 8710.1186/s13045-022-01307-2 ↗
35. Zheng · Adv. Mater. · 2022 · 34 · 220120010.1002/adma.202201200 ↗
36. Hao · Adv. Sci. · 2020 · 7 · 20011853
37. Lee · J. Am. Chem. Soc. · 2012 · 134 · 1266810.1021/ja303998y ↗
38. Segarra-Maset · Chem. Soc. Rev. · 2013 · 42 · 708610.1039/C2CS35436E ↗